TY - JOUR
T1 - Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
AU - Keppler-Hafkemeyer, Andrea
AU - Greil, Christine
AU - Wratil, Paul R.
AU - Shoumariyeh, Khalid
AU - Stern, Marcel
AU - Hafkemeyer, Annika
AU - Ashok, Driti
AU - Hollaus, Alexandra
AU - Lupoli, Gaia
AU - Priller, Alina
AU - Bischof, Marie L.
AU - Ihorst, Gabriele
AU - Engelhardt, Monika
AU - Marks, Reinhard
AU - Finke, Jürgen
AU - Bertrand, Hannah
AU - Dächert, Christopher
AU - Muenchhoff, Maximilian
AU - Badell, Irina
AU - Emmerich, Florian
AU - Halder, Hridi
AU - Spaeth, Patricia M.
AU - Knolle, Percy A.
AU - Protzer, Ulrike
AU - von Bergwelt-Baildon, Michael
AU - Duyster, Justus
AU - Hartmann, Tanja N.
AU - Moosmann, Andreas
AU - Keppler, Oliver T.
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.
AB - Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.
UR - https://www.scopus.com/pages/publications/85144425353
U2 - 10.1038/s43018-022-00502-x
DO - 10.1038/s43018-022-00502-x
M3 - Article
AN - SCOPUS:85144425353
SN - 2662-1347
VL - 4
SP - 81
EP - 95
JO - Nature Cancer
JF - Nature Cancer
IS - 1
ER -